ArticleFrontiers in neurology2025

Clinical utility of neurofilament light chain as a biomarker for disease onset and progression in hereditary transthyretin amyloidosis.

Álvaro Gragera-Martínez et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.